DNA & Blood Clots: 180% Risk Increase
- Researchers in Sweden have identified three genetic variants that substantially elevate the risk of venous blood clots, also known as venous thrombosis, particularly in the legs.
- Unlike arterial clots, which often stem from plaque buildup and can led to heart attack or stroke, venous clots typically form in the legs due to prolonged blood...
- In Sweden alone, over 10,000 individuals experience venous thromboembolism annually, and this number is rising.
A groundbreaking study reveals that certain genetic variants can elevate your risk of venous blood clots by up to 180%. This thorough report dives into the critical link between DNA and blood clot formation,highlighting three newly discovered gene variants,and how they significantly amplify your susceptibility to this possibly life-threatening condition. Learn about the specific genes—ABO, F8, and VWF—identified by researchers, and understand the implications of multiple genetic risk factors. Besides,discover how lifestyle changes and preventative measures can play a vital role in risk reduction. News Directory 3 provides crucial insights into global health concerns, emphasizing strategies to mitigate your risk of venous thrombosis. what personalized treatment approaches are on the horizon? Discover what’s next in the fight against blood clots.
Genetic Variants Significantly Increase Risk of Blood Clots
Researchers in Sweden have identified three genetic variants that substantially elevate the risk of venous blood clots, also known as venous thrombosis, particularly in the legs. The Lund University team’s findings highlight new avenues for understanding and potentially preventing this common and potentially fatal condition.
Unlike arterial clots, which often stem from plaque buildup and can led to heart attack or stroke, venous clots typically form in the legs due to prolonged blood stagnation. If these clots break free and travel to the lungs, they can cause a pulmonary embolism, a life-threatening event. According to Bengt Zöller, a professor at Lund University and specialist at Skåne University Hospital, venous thrombosis is a major global health concern, often overshadowed by arterial issues.
In Sweden alone, over 10,000 individuals experience venous thromboembolism annually, and this number is rising. Factors contributing to this increase include an aging population, as the risk of blood clots rises wiht age. Overweight individuals and taller people also face elevated risk.
Muscle activity aids blood flow in veins, and prolonged inactivity can be detrimental.Vein valves prevent backflow, but their damage increases clot risk. Taller individuals might potentially be more susceptible due to longer veins and greater distance for blood to travel back to the heart. While high blood pressure and cholesterol are major risk factors for arterial clots,obesity is a primary concern for venous clots,negatively impacting circulation and clotting factors. Diet also plays a role; ultra-processed foods may increase risk, while plant-based diets may reduce it.
Specific situations also elevate the risk of venous blood clots. Extended air travel or bed rest can reduce blood flow, increasing the likelihood of clot formation. Surgery or inflammation can damage vessel walls, promoting clotting. Pregnancy also increases clotting factors while decreasing protective proteins.
“In these risk situations, prophylaxis in the form of blood thinners may be particularly significant if other risk factors are also present,” said Zöller.
Genetic factors also play a significant role.In Sweden, a high prevalence of APC resistance exists due to the Factor V Leiden mutation, affecting about 10% of the population. Zöller’s team identified three additional gene variants—ABO, F8, and VWF—that, combined, pose a similar risk to Factor V Leiden. These variants can increase the risk of venous thrombosis by 10 to 30 percent individually, and up to 180 percent when multiple variants are present.
“And the more of these variants a person has – the higher the risk. An individual with five of these gene variants has a 180 per cent higher risk of venous thrombosis,” Zöller explained.
These genetic variants are found in populations worldwide, prompting further research into how the number of risk genes affects anticoagulant treatment duration.
What’s next
Future research will focus on tailoring treatment strategies based on individual risk assessments, incorporating both genetic and lifestyle factors to optimize patient care and prevent venous thrombosis.